1183, -1184, -1185, -1186, -1187, -1188, -1189, -1190 Astrazeneca Pharmaceuticals… v. Apotex Corp.

United States Court of Appeals
for the Federal Circuit
______________________
February 9. 2012
ERRATA
______________________
2011-1182, -1183, -1184, -1185, -1186, -1187, -1188, -1189,
-1190
ASTRAZENECA PHARMACEUTICALS LP,
ASTRAZENECA AB, IPR PHARMACEUTICALS INC.,
and THE BRIGHAM AND WOMEN’S HOSPITAL, INC.,
Plaintiffs-Appellants,
v.
APOTEX CORP.,
Defendant-Appellee,
and
AUROBINDO PHARMA LIMITED,
Defendant-Appellee,
and
COBALT PHARMACEUTICALS INC.
and COBALT LABORATORIES INC.,
Defendants-Appellees,
and
GLENMARK GENERICS INC. USA,
Defendant-Appellee,
and

-- 1 of 2 --

MYLAN PHARMACEUTICALS INC.,
Defendant-Appellee,
and
PAR PHARMACEUTICALS, INC.,
Defendant-Appellee,
and
SUN PHARMACEUTICAL INDUSTRIES, LTD.,
Defendant-Appellee,
and
TEVA PHARMACEUTICALS USA, INC.,
Defendant-Appellee,
and
TORRENT PHARMA INC. and
TORRENT PHARMACEUTICALS LTD.,
Defendants.
______________________
Decided: February 24, 2012
Precedential Opinion
______________________
Please make the following change:
Page 3, correction of
Shane A. Brunner, Mechant & Gould, P.C. of Madison,
Wisconsin, argued for defendant-appellee “Aurobindo
Pharma Limited”
H. Ketto Sabharwal to “H. Keeto Sabharwal”

-- 2 of 2 --